• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Loss of reticulocalbin 2 lowers blood pressure and restrains angiotensin II-induced hypertension in vivo.
Abstract Hypertension affects over one billion people worldwide and increases risk for heart failure, stroke and chronic kidney disease. Despite high prevalence and devastating impact, its etiology still remains poorly understood for most hypertensive cases. Rcn2, encoding reticulocalbin 2, is a candidate gene for atherosclerosis we previously demonstrated in mice. Here we identified Rcn2 as a novel regulator of blood pressure in mice. Rcn2 was dramatically upregulated in arteries undergoing structural remodeling. Deletion of Rcn2 lowered basal blood pressure and attenuated angiotensin II-induced hypertension in C...
Source: Am J Physiol Renal P... - April 2, 2019 Category: Urology & Nephrology Authors: Li J, Cechova S, Wang L, Isakson BE, Le T, Shi W Tags: Am J Physiol Renal Physiol Source Type: research

The Impact of APOL1 on Chronic Kidney Disease and Hypertension
This article reviews relationships between mild to moderate essential hypertension and chronic kidney disease with a focus on the role of APOL1 in development of hypertension. Available evidence strongly supports that APOL1 renal-risk variants associate with glomerulosclerosis in African Americans, which then causes secondary hypertension, not with essential hypertension per se.
Source: Advances in Chronic Kidney Disease - April 24, 2019 Category: Urology & Nephrology Source Type: research

Free 25-Vitamin D Is Correlated with Cardiovascular Events in Prevalent Hemodialysis Patients but Not with Markers of Renal Mineral Bone Disease
In conclusion, our study shows that free vitamin D serum concentrations are independently associated with major cardiovascular events in chronic kidney disease patients on dialysis.Kidney Blood Press Res
Source: Kidney and Blood Pressure Research - June 14, 2019 Category: Urology & Nephrology Source Type: research

Summary: International Kidney Cancer Symposium
Conclusions:  Ideal ischemia time is 20-25 minutes or less improves short and long term renal function. >25 minutes carried 5 year risk of new onset stage 4 CKD No differences on GFR for cold vs. warm ischemia times Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.  No ischemia preserves renal function better than warm. Longer cold ischemia times were equivalent to shorter warm ischemia times. Quality and quantity of the remaining kidney is associated with ultimate renal function. Robotics in RCC Surgery Gennady Bratslavsky, MD The opening question ...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news

GFR-Specific versus GFR-Agnostic Cutoffs for Parathyroid Hormone and Fibroblast Growth Factor-23 in Advanced Chronic Kidney Disease.
CONCLUSION: GFR-specific risk-based cutoffs for PTH1-84 and FGF-23 may facilitate more meaningful risk stratification in advanced CKD than current GFR-agnostic reference ranges derived from healthy adults. This may be most applicable in those with severely reduced GFR. PMID: 31238301 [PubMed - as supplied by publisher]
Source: American Journal of Nephrology - June 24, 2019 Category: Urology & Nephrology Authors: Canney M, Djurdjev O, Tang M, Zierold C, Blocki F, Wolf M, Levin A Tags: Am J Nephrol Source Type: research

Serum Calcification Propensity and Clinical Events in CKD.
CONCLUSIONS: Among patients with CKD stages 2-4, higher serum calcification propensity is associated with atherosclerotic cardiovascular disease events, ESKD, and all-cause mortality, but this association was not independent of kidney function. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_10_28_CJN04710419.mp3. PMID: 31658949 [PubMed - as supplied by publisher]
Source: Clinical Journal of the American Society of Nephrology : CJASN - October 27, 2019 Category: Urology & Nephrology Authors: Bundy JD, Cai X, Mehta RC, Scialla JJ, de Boer IH, Hsu CY, Go AS, Dobre MA, Chen J, Rao PS, Leonard MB, Lash JP, Block GA, Townsend RR, Feldman HI, Smith ER, Pasch A, Isakova T, CRIC Study Investigators Tags: Clin J Am Soc Nephrol Source Type: research

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
CONCLUSIONS: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. TRIAL REGISTRATION: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049. PMID: 31665733 [PubMed - as supplied by publisher]
Source: American Journal of Nephrology - October 29, 2019 Category: Urology & Nephrology Authors: Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B, FIGARO-DKD study investigators Tags: Am J Nephrol Source Type: research

Effect of Chronic Kidney Disease on Cardiovascular Events: An Epidemiological Aspect from SPRINT Trial.
CONCLUSIONS: SPRINT is the first trial revealing that CKD is an independent risk factor for CVD. However, CKD could not be considered as a CVD risk equivalent. In the presence of CKD, with intensive blood pressure reduction the chance of AKI is dramatically increased. PMID: 31705750 [PubMed - in process]
Source: Iranian Journal of Kidney Diseases - November 12, 2019 Category: Urology & Nephrology Tags: Iran J Kidney Dis Source Type: research

Potassium binding for conservative and preservative management of chronic kidney disease
In conclusion, there are new well tolerated and effective K+-binding agents for acutely and chronically managing hyperkalemia.
Source: Current Opinion in Nephrology and Hypertension - November 29, 2019 Category: Urology & Nephrology Tags: NOVEL THERAPEUTIC APPROACHES IN NEPHROLOGY AND HYPERTENSION: Edited by Kamyar Kalantar-Zadeh and Ekamol Tantisattamo Source Type: research

Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus.
CONCLUSION: In T2DM patients, CKD presence was associated with higher risk of modified MACE, HF, and ACM. This may have risk-stratification implications for T2DM patients based on background CKD and highlights the potential importance of novel renoprotective strategies. PMID: 31812955 [PubMed - as supplied by publisher]
Source: American Journal of Nephrology - December 5, 2019 Category: Urology & Nephrology Authors: Cherney DZI, Repetto E, Wheeler DC, Arnold SV, MacLachlan S, Hunt PR, Chen H, Vora J, Kosiborod M Tags: Am J Nephrol Source Type: research

Myeloperoxidase and the Risk of CKD Progression, Cardiovascular Disease, and Death in the Chronic Renal Insufficiency Cohort (CRIC) Study
ConclusionsHigher MPO level was associated with increased risk for CKD progression, but not with CVD and death in patients with CKD from CRIC. Whether therapies aimed at reducing MPO activity can result in improved clinical outcomes is yet to be determined.
Source: American Journal of Kidney Diseases - December 20, 2019 Category: Urology & Nephrology Source Type: research

The association between CHA2DS2-VASc score and erectile dysfunction: a cross-sectional study
Conclusion: CHA2DS2-VASc score can be used to detect Erectile dysfunction in patients who are admitted to the cardiology outpatient clinics.
Source: International Braz J Urol - December 20, 2019 Category: Urology & Nephrology Source Type: research

Selected cardiovascular risk factors in early stages of chronic kidney disease
AbstractCardiovascular diseases, including hypertension, congestive heart failure, myocardial infarction, stroke and atherosclerosis, are common in patients with chronic kidney disease. Aside from the standard biomarkers, measured to determine cardiovascular risk, new ones have emerged: markers of oxidative stress, apoptosis, inflammation, vascular endothelium dysfunction, atherosclerosis, organ calcification and fibrosis. Unfortunately, their utility for routine clinical application remains to be elucidated. A causal relationship between new markers and cardiovascular diseases in patients with chronic kidney disease remai...
Source: International Urology and Nephrology - January 17, 2020 Category: Urology & Nephrology Source Type: research

SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
Abstract Sodium-glucose co-transporter-2 (SGLT2) inhibitor drugs are effective for treatment of type-2 diabetes mellitus. These medications target the SGLT2 transporter in the proximal convoluted tubule to prevent reabsorption of filtered glucose, resulting in glucosuria. Other clinically meaningful benefits beyond glycemic control include reductions in blood pressure, weight, and albuminuria. Three large clinical trials and subsequent meta-analyses studying SGLT2 inhibitors demonstrated significant cardiovascular benefits including reductions in heart failure hospitalizations, as well as reduced risk of myocardia...
Source: Journal of Nephrology - February 17, 2020 Category: Urology & Nephrology Authors: Baker ML, Perazella MA Tags: J Nephrol Source Type: research

Association of trimethylamine N-Oxide with cardiovascular and all-cause mortality in hemodialysis patients.
CONCLUSIONS: High plasma TMAO level is significantly and independently associated with cardiovascular and all-cause mortality in HD patients. PMID: 32985309 [PubMed - in process]
Source: Renal Failure - September 29, 2020 Category: Urology & Nephrology Tags: Ren Fail Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11